Noël Knops1,2, Jean Herman1, Maria van Dyck1, Yasaman Ramazani2, Edward Debbaut1, Rita van Damme-Lombaerts1, Elena Levtchenko1,2, Lambertus P van den Heuvel2, Steffen Fieuws3, Dirk Kuypers4. 1. Dept. of Pediatric Nephrology and Solid Organ Transplantation, University Hospitals Leuven, Herestraat 49, Leuven, Belgium. 2. Laboratory for Pediatrics, Dept. of Development & Regeneration, KU Leuven, O&N3, bus 817, Leuven, Belgium. 3. Interuniversity Institute for Biostatistics and statistical Bioinformatics, University of Leuven, Belgium, Kapucijnenvoer 35, Leuven, Belgium. 4. Dept. of Nephrology and Renal Transplantation, University Hospitals Leuven, Herestraat 49, Leuven, Belgium.
Abstract
AIMS: Despite longstanding recognition of significant age-dependent differences in drug disposition during childhood, the exact course and the underlying mechanisms are not known. Our aim was to determine the course and determinants of individual relative dose requirements, during long-term follow-up in children on tacrolimus. METHODS: This was a cohort study in a tertiary hospital with standardized annual pharmacokinetic (PK) follow-up (AUC0-12hr ) in recipients of a renal allograft (≤19 years), between 1998 and 2015. In addition, the presence of relevant pharmacogenetic variants was determined. The evolution of dose-corrected exposure was evaluated using mixed models. RESULTS: A total of 184 PK visits by 43 children were included in the study (median age: 14.6). AUC0-12h corrected for dose per kg demonstrated a biphasic course: annual increase 4.4% (CI: 0.3-8.7%) until ±14 years of age, followed by 13.4% increase (CI 8.7-18.3%). Moreover, exposure corrected for dose per m2 proved stable until 14 years (+0.8% annually; CI: -3.0 to +4.8%), followed by a steep increase ≥14 years (+11%; CI: 7.0-16.0%). Analysis according to bone maturation instead of age demonstrated a similar course with a distinct divergence at TW2: 800 (P = 0.01). Genetic variation in CYP3A4, CYP3A5, and CYP3A7 was associated with altered dose requirements, independent of age. CONCLUSIONS: Children exhibit a biphasic course in tacrolimus disposition characterized by a high and stable drug clearance until a specific phase in pubertal development (TW2: 800 at age: ±14 years), followed by an important decline in relative dose requirements thereafter. Pharmacogenetic variation demonstrated an age/puberty independent effect. We suggest a critical reappraisal of current paediatric dosing algorithms for tacrolimus and drugs with a similar disposition.
AIMS: Despite longstanding recognition of significant age-dependent differences in drug disposition during childhood, the exact course and the underlying mechanisms are not known. Our aim was to determine the course and determinants of individual relative dose requirements, during long-term follow-up in children on tacrolimus. METHODS: This was a cohort study in a tertiary hospital with standardized annual pharmacokinetic (PK) follow-up (AUC0-12hr ) in recipients of a renal allograft (≤19 years), between 1998 and 2015. In addition, the presence of relevant pharmacogenetic variants was determined. The evolution of dose-corrected exposure was evaluated using mixed models. RESULTS: A total of 184 PK visits by 43 children were included in the study (median age: 14.6). AUC0-12h corrected for dose per kg demonstrated a biphasic course: annual increase 4.4% (CI: 0.3-8.7%) until ±14 years of age, followed by 13.4% increase (CI 8.7-18.3%). Moreover, exposure corrected for dose per m2 proved stable until 14 years (+0.8% annually; CI: -3.0 to +4.8%), followed by a steep increase ≥14 years (+11%; CI: 7.0-16.0%). Analysis according to bone maturation instead of age demonstrated a similar course with a distinct divergence at TW2: 800 (P = 0.01). Genetic variation in CYP3A4, CYP3A5, and CYP3A7 was associated with altered dose requirements, independent of age. CONCLUSIONS:Children exhibit a biphasic course in tacrolimus disposition characterized by a high and stable drug clearance until a specific phase in pubertal development (TW2: 800 at age: ±14 years), followed by an important decline in relative dose requirements thereafter. Pharmacogenetic variation demonstrated an age/puberty independent effect. We suggest a critical reappraisal of current paediatric dosing algorithms for tacrolimus and drugs with a similar disposition.
Authors: Violette M G J Gijsen; Ron H N van Schaik; Offie P Soldin; Steven J Soldin; Irena Nulman; Gideon Koren; Saskia N de Wildt Journal: Ther Drug Monit Date: 2014-04 Impact factor: 3.681
Authors: Iain A M Macphee; Salim Fredericks; Maha Mohamed; Michelle Moreton; Nicholas D Carter; Atholl Johnston; Lawrence Goldberg; David W Holt Journal: Transplantation Date: 2005-02-27 Impact factor: 4.939
Authors: Oliver Burk; Heike Tegude; Ina Koch; Elisabeth Hustert; Renzo Wolbold; Hartmut Glaeser; Kathrin Klein; Martin F Fromm; Andreas K Nuessler; Peter Neuhaus; Ulrich M Zanger; Michel Eichelbaum; Leszek Wojnowski Journal: J Biol Chem Date: 2002-04-08 Impact factor: 5.157
Authors: Agnieszka A Prytuła; Karlien Cransberg; Antonia H M Bouts; Ron H N van Schaik; Huib de Jong; Saskia N de Wildt; Ron A A Mathôt Journal: Clin Pharmacokinet Date: 2016-09 Impact factor: 6.447
Authors: Noël Knops; Jean Herman; Maria van Dyck; Yasaman Ramazani; Edward Debbaut; Rita van Damme-Lombaerts; Elena Levtchenko; Lambertus P van den Heuvel; Steffen Fieuws; Dirk Kuypers Journal: Br J Clin Pharmacol Date: 2016-12-13 Impact factor: 4.335
Authors: Noël Knops; Jean Herman; Maria van Dyck; Yasaman Ramazani; Edward Debbaut; Rita van Damme-Lombaerts; Elena Levtchenko; Lambertus P van den Heuvel; Steffen Fieuws; Dirk Kuypers Journal: Br J Clin Pharmacol Date: 2016-12-13 Impact factor: 4.335
Authors: Amy L Pasternak; Vincent D Marshall; Christina L Gersch; James M Rae; Michael Englesbe; Jeong M Park Journal: Pharmgenomics Pers Med Date: 2021-03-12
Authors: Ingvild Andrea Kindem; Anna Bjerre; Anders Åsberg; Karsten Midtvedt; Stein Bergan; Nils Tore Vethe Journal: Ther Drug Monit Date: 2021-06-01 Impact factor: 3.681